Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Health Yuan launches innovative inhaled PDE4 inhibitor, promoting new breakthroughs in the treatment of COPD and asthma
Published Time：
2024-11-25
Recently, the world welcomed the 23rd World Chronic Obstructive Pulmonary Disease Day (COPD Day). While many patients suffer from this disease, many innovative pharmaceutical companies are deploying resources into this field, constantly achieving new breakthroughs.
Jiankangyuan Pharmaceutical Group, a leading domestic respiratory preparation company, has launched another innovative drug—an inhaled PDE4 inhibitor for chronic obstructive pulmonary disease (COPD). This marks a further expansion of the company's innovative R&D layout in the respiratory field.
COPD is a common chronic respiratory disease that damages patients' lungs and leads to progressive decline in lung function. Moderate to severe COPD is often accompanied by persistent inflammation. This inflammation not only exacerbates airway obstruction but also further accelerates the disease progression.
Currently, the main respiratory anti-inflammatory drugs for COPD management on the market are corticosteroids (ICS). For moderate to severe patients, especially those with acute exacerbations, their therapeutic effect is somewhat limited.
Innovative inhaled PDE4 inhibitor:
Precisely targets COPD inflammatory cells, reducing side effects
PDE is short for Phosphodiesterase, a type of enzyme, similar to a "cleaner" in the human body. Its family members are numerous and have clear divisions of labor. In recent years, through extensive research in the medical field, more selective PDE families, mainly PDE4, have been discovered that can precisely target inflammatory cells in COPD. Due to its anti-inflammatory activity, some experts believe that long-term use may improve lung function in severe COPD patients and reduce the number of acute exacerbations.
In the past, many international pharmaceutical companies have vigorously developed PDE4 inhibitors, such as the oral COPD drug roflumilast. However, although past results have shown some efficacy in improving lung function and reducing acute exacerbations, its systemic administration has led to significant side effects, such as diarrhea, nausea, abdominal pain, sleep disorders, and headaches, which have to some extent limited its widespread clinical application.
Against this backdrop, there is an urgent clinical need for a new inhaled PDE4 inhibitor. The inhaled PDE4 inhibitor newly launched by Jiankangyuan, due to its local administration characteristics, can reduce systemic side effects while retaining efficacy. This is also the first PDE4 inhaled formulation pipeline launched by a Chinese company.
Effectively reduces the frequency of COPD exacerbations
Data show that compared with oral PDE4 drugs, this innovative inhaled agent, through inhalation administration, maintains high levels of intracellular cAMP, effectively inhibiting the release of inflammatory factors, reducing protease activity and oxidant production, creating a strong anti-inflammatory environment, and significantly alleviating inflammatory symptoms in COPD patients.
While significantly reducing systemic drug exposure, it also reduces the risk of systemic side effects, ensuring treatment safety. This innovative inhaled inhibitor, as a drug with a new mechanism in the COPD field, through anti-inflammation, improvement of lung function, and modulation of immune responses, directly targets lung lesions and can Effectively reduces the frequency of COPD exacerbations ， bring new hope for treatment in this field.
At the same time, the broad-spectrum anti-inflammatory properties of asthma treatment also shows potential 。 It is reported that PDE4 inhibitors, by continuously maintaining high levels of intracellular cAMP, can effectively inhibit T cell activation and regulate inflammatory cell function. In addition, it can comprehensively inhibit the release of inflammatory factors, reduce protease activity and oxidant production, creating a strong anti-inflammatory environment, opening up new possibilities for the treatment of asthma patients and other related diseases, and demonstrating its broad prospects in the treatment of respiratory diseases.
Jiankangyuan's Respiratory Strategy
As a leading enterprise in China's inhaled formulation field, Jiankangyuan has always regarded the inhaled formulation sector as one of the core elements of the company's strategic development. The company continues to increase investment in independent R&D and actively introduces and develops advanced innovative drugs at home and abroad, continuously enriching its Big Pharma-level product pipeline.
Currently, Jiankangyuan has successfully launched 10 varieties and 14 specifications of respiratory products to the market and has reserved more than 20 varieties under research, including 10 innovative respiratory drugs, achieving full coverage of asthma and COPD inhaled treatment drugs and building a comprehensive layout from existing mature products to future potential new drugs.
The launch of this inhaled PDE4 inhibitor will further enrich Jiankangyuan's innovative drug pipeline in the respiratory field and consolidate the company's leading position in the respiratory field. At the same time, Jiankangyuan will make every effort to promote the R&D process of this innovative drug, striving to transform it into a clinical treatment plan as soon as possible, and contribute more "healthy" power to the prevention and control of COPD in China and even the world.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.